First dose of potential new medicines to humans: how animals help

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Nature reviews. Drug discovery

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd1329PMID 15031736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs.

  2009cited by this paper
• Drug-induced hepatotoxicity.

  2003cited by this paper
• The impact of drug-induced QT interval prolongation on drug discovery and development

  2003cited by this paper
• Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing.

  2003cited by this paper
• Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

  2003cited by this paper
• Designing safer drugs: (Q)SAR-based identification of mutagens and carcinogens.

  2003cited by this paper
• Toxicology rethinks its central belief

  2003cited by this paper
• Preclinical safety evaluation of biotechnology-derived pharmaceuticals

  2002cited by this paper
• The role of time as a quantifiable variable of toxicity and the experimental conditions when Haber's c x t product can be observed: implications for therapeutics.

  2001cited by this paper
• Concordance of the toxicity of pharmaceuticals in humans and in animals.

  2000cited by this paper
• QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

  2000cited by this paper
• Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation

  2000cited by this paper
• QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development.

  1999cited by this paper
• The Nuremberg Code: Hippocratic ethics and human rights.

  1998cited by this paper
• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper
• Report of validation study of assessment of direct immunotoxicity in the rat. The ICICIS Group Investigators. International Collaborative Immunotoxicity Study.

  1998cited by this paper
• The significance of the Nuremberg Code.

  1998cited by this paper
• What does the clinician want to know from the toxicologist?

  1998cited by this paper
• The significance of the Nuremberg Code.

  1998cited by this paper
• Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus.

  1998cited by this paper
• Immunotoxicology assessment in the pharmaceutical industry.

  1998cited by this paper
• Serum transaminase elevations as indicators of hepatic injury following the administration of drugs.

  1998cited by this paper
• Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.

  1998cited by this paper
• The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods

  1998cited by this paper
• Fifty years later: the significance of the Nuremberg Code.

  1997cited by this paper
• Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals.

  1997cited by this paper
• Response to Monro and Mehta proposal for use of single‐dose toxicology studies to support single‐dose studies of new drugs in humans

  1996cited by this paper
• Are single‐dose toxicology studies in animals adequate to support single doses of a new drug in humans?

  1996cited by this paper
• A Collaborative Study in Japan on Optimal Treatment Period and Parameters for Detection of Male Fertility Disorders Induced by Drugs in Rats

  1995cited by this paper
• Predictability of clinical adverse reactions of drugs by general pharmacology studies.

  1995cited by this paper
• Drug-induced hepatotoxicity.

  1995cited by this paper
• Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki.

  1994cited by this paper
• [Detection of Pasteurella multocida toxin - a comparison of in vitro and in vivo methods]

  1994cited by this paper
• Animal Toxicity Studies: Their Relevance for Man

  1991cited by this paper
• Detecting and evaluating chemical-induced lung damage in experimental animals.

  1987cited by this paper
• Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980).

  1986cited by this paper
• Comparison of Canine and Human Gastrointestinal Physiology

  1986cited by this paper
• Relation of preclinical toxicology to findings in early clinical trials.

  1986cited by this paper
• Mutagenicity in drug development: interpretation and significance of test results.

  1985cited by this paper
• Adverse Drug Reactions

  1985cited by this paper
• Toxicological assessment of the hemostatic system, regulatory requirements, and industry practice.

  1984cited by this paper
• The effects of drugs and chemicals upon the structure of the adrenal gland.

  1984cited by this paper
• Correlation of human hepatotoxicants with hepatic damage in animals.

  1982cited by this paper
• Drug Safety Tests and Subsequent Clinical Experience

  1978cited by this paper
• The Role of Metabolish Studies in Drug Safety Evaluation

  1976cited by this paper
• The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man

  1970cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper
• Predicting anticancer drug effects in man from laboratory animal studies.

  1962cited by this paper
• Forecasting drug effects in man from studies in laboratory animals.

  1961cited by this paper
• Abdominal exploration for gastrointestinal bleeding of obscure origin.

  1961cited by this paper
• PATHOLOGIC EFFECTS OF ELIXIR OF SULFANILAMIDE (DIETHYLENE GLYCOL) POISONING: A CLINICAL AND EXPERIMENTAL CORRELATION: FINAL REPORT

  1938cited by this paper

• Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017.

  2025cites this paper
• Current practices on the measurement of electrocardiogram and hemodynamic parameters in non-rodent species in regulatory safety assessment studies.

  2025cites this paper
• A Systematic and Ethnobotanical Review of Ashwagandha's (Withania Somnifera) Teratogenic and Abortifacient Potentials.

  2025cites this paper
• Application of new approach methodologies for nonclinical safety assessment of drug candidates

  2025cites this paper
• Translation of nonclinical to clinical safety findings for 27 biotherapeutics.

  2024cites this paper
• Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?

  2024cites this paper
• The Potential of Composite Cements for Wound Healing in Rats

  2024cites this paper
• Comparison of electrocardiogram and blood pressure recording methods in non-rodent toxicology studies: A retrospective analysis.

  2024cites this paper
• Revolutionizing healthcare: Emerging frontiers in 3D bioprinting of tissues and organs

  2024cites this paper
• Four-week repeated exposure to tire-derived 6-PPD quinone causes multiple organ injury in male BALB/c mice.

  2023cites this paper
• Theobroma cacao fortified-feed ameliorates potassium bromate-induced oxidative damage in male Wistar rat

  2023cites this paper
• Contactless mechanical stimulation of tissue engineered constructs: Development and validation of an air-pulse device.

  2023cites this paper
• Pharmacodynamic study in multi-animal models on the efficacy and optimal dosage of antiviral oral liquid for children

  2023cites this paper
• Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept

  2022cites this paper
• Animal Models in Toxicologic Research: Dog

  2022cites this paper
• Physiological oxygen and co-culture with human fibroblasts facilitate in vivo-like properties in human renal proximal tubular epithelial cells.

  2022cites this paper
• A comparison of activity data generated from cardiovascular telemetry studies - With quantitative open field locomotor studies in Wistar Han rats.

  2022cites this paper
• A systems approach reveals species differences in hepatic stress response capacity

  2022cites this paper
• Rats exhibit higher hepatic stress response pathway capacities compared with mice and humans

  2022cites this paper
• Microfluidics for Drug Development: From Synthesis to Evaluation.

  2021cites this paper
• Exploring CNS Effects of American Traditional Medicines using Zebrafish Models

  2021cites this paper
• Models of Drug Induced Liver Injury (DILI)-Current Issues and Future Perspectives

  2021cites this paper
• Improving the sensitivity of T1 contrast-enhanced MRI and sensitive diagnosing tumors with ultralow doses of MnO octahedrons

  2021cites this paper
• Peptide drugs for photopharmacology: how much of a safety advantage can be gained by photocontrol?

  2020cites this paper
• Bioactivation of diclofenac in human hepatocytes and the proposed human hepatic proteins modified by reactive metabolites

  2020cites this paper
• Factors affecting the reliability of behavioral assessments for rodent osteoarthritis models

  2020cites this paper
• Method of myelinating isolated motoneurons

  2020cites this paper
• Machine Perfusion of the Liver: Applications Beyond Transplantation

  2020cites this paper
• Toxicology Paradise: Sorting Out Adverse and Non-adverse Findings in Animal Toxicity Studies

  2020cites this paper
• Grading animal distress and side effects of therapies

  2020cites this paper
• Characterization of a long-term mouse primary liver 3D tissue model recapitulating innate-immune responses and drug-induced liver toxicity

  2020cites this paper
• Novel experimental work on animals: Law and ethics’ perspective

  2020cites this paper
• Kidney Safety Assessment: Current Practices in Drug Development.

  2019cites this paper
• Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis

  2019cites this paper
• Safety Assessment of Pharmaceuticals

  2019cites this paper
• Current trends in in silico, in vitro toxicology, and safety biomarkers in early drug development

  2019cites this paper
• High-Throughput Screening and Hazard Testing Prioritization

  2019cites this paper
• A thermoplastic microfluidic microphysiological system to recapitulate hepatic function and multicellular interactions

  2019cites this paper
• Biotechnology and Bioengineering: Volume 116, Number 7, July 2019

  2019cites this paper
• Microfluidic Cell Culture Platforms to Capture Hepatic Physiology and Complex Cellular Interactions

  2018cites this paper
• TISSUES 2.0: an integrative web resource on mammalian tissue expression

  2018cites this paper
• A combined tissue‐engineered/in silico signature tool patient stratification in lung cancer

  2018cites this paper
• A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans

  2018cites this paper
• The Hematopoietic System: Evaluation and Data Interpretation in Nonclinical Safety Studies

  2018cites this paper
• Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms

  2018cites this paper
• Pathophysiological investigations, anxiolytic effects and interaction of a semisynthetic riparin with benzodiazepine receptors.

  2018cites this paper
• Nonclinical Safety Pharmacology

  2018cites this paper
• Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives

  2018cites this paper
• Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge

  2018cites this paper
• Future of Regulatory Safety Assessments

  2018cites this paper
• Better science for safer medicines: the human imperative

  2018cites this paper
• TISSUES 2.0: an integrative web resource on mammalian tissue expression

  2018cites this paper
• Cosmetic industry requirements regarding skin models for cosmetic testing

  2018cites this paper
• Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity

  2017cites this paper
• Towards the assessment of human-relevant repeated dose toxicity using an in vitro systems toxicological approach

  2017influential citation
• Biomarkers in Veterinary Medicine.

  2017cites this paper
• Human biology-based drug safety evaluation: scientific rationale, current status and future challenges

  2017cites this paper
• White Paper: BioMed21 Workshop (June 2017)

  2017cites this paper
• Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds.

  2017cites this paper
• New methods of multiscale chemical space analysis : visualization of structure-activity relationships and structural pattern extraction

  2017cites this paper
• Dose estimation, conversion and translation from animal to human and human to animal for clinical and animal studies.

  2017cites this paper
• Limitations of Pathology and Animal Models

  2017cites this paper
• Chapter 41 – Modern Drug Discovery and Development

  2017cites this paper
• Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.

  2017cites this paper
• Nonclinical Safety and Toxicology.

  2016cites this paper
• Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions

  2016cites this paper
• New Approaches to Drug Discovery

  2016cites this paper
• Skin Bioprinting: Impending Reality or Fantasy?

  2016cites this paper
• Model Selection and Scaling (Allometry)

  2016cites this paper
• A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond

  2016cites this paper
• A retrospective evaluation of species-specific sensitivity for neurological signs in toxicological studies: Is the dog more sensitive than the non-human primate?

  2016cites this paper
• The Use of Minipig in Drug Discovery and Development

  2016cites this paper
• Pharmacokinetics in Drug Development

  2016cites this paper
• Synthetic mammalian neuromuscular junction and method of making (US)

  2016cites this paper
• Investigative safety strategies to improve success in drug development

  2016cites this paper
• Biomarkers, Cell Models, and In Vitro Assays for Gastrointestinal Toxicology

  2016cites this paper
• How do researchers decide early clinical trials?

  2016cites this paper
• A human liver microphysiology platform for investigating physiology, drug safety, and disease models

  2016cites this paper
• Method of co-culturing mammalian muscle cells and motoneurons

  2016cites this paper
• Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies

  2016cites this paper
• Human Pluripotent Stem Cell‐Derived Cardiomyocytes

  2016cites this paper
• Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets

  2016cites this paper
• Scientific and Regulatory Policy Committee

  2016cites this paper
• In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.

  2016cites this paper
• Fluorescent protein biosensors applied to microphysiological systems

  2015cites this paper
• Prediction of drug induced liver injury using molecular and biological descriptors.

  2015cites this paper
• The Application of Omics Technologies to the Study of Mammalian Toxicology

  2015cites this paper
• Developmental toxicity in rats of a hemoglobin-based oxygen carrier results from impeded function of the inverted visceral yolk sac

  2015cites this paper
• Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?

  2015cites this paper
• Ultrastructural alterations of the inferior alveolar nerve in wistar rats after alendronate administration per os: hypothesis for the generation of the "numb chin syndrome"

  2015cites this paper
• Biobanking Trends, Challenges, and Opportunities

  2015cites this paper
• Detecção do composto iqg-607 : uma etapa essencial para futuros estudos de farmacocinética

  2015cites this paper
• Antibody Drug Conjugates: Nonclinical Safety Considerations

  2015cites this paper
• Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure?

  2015cites this paper
• Safety Pharmacology in Drug Discovery and Development.

  2015cites this paper
• Drug biokinetic and toxicity assessments in rat and human primary hepatocytes and HepaRG cells within the EU-funded Predict-IV project.

  2015cites this paper
• Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms

  2015cites this paper
• Bone marrow spontaneous lesions in rodents from nonclinical 104-week carcinogenicity studies.

  2015cites this paper
• Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

  2015cites this paper
• CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology.

  2015cites this paper